BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally. BPL-003 was shown to be safe and well-tolerated with a predictable ...

NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even ...

Shares of atai Life Sciences N.V. (ATAI) have been struggling lately and have lost 6.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean ...

Good morning, everyone, and welcome back to H.C. Wainwright's 27th Annual Global Investment Conference held from September 8 to September 10, 2025. My name is Patrick Trucchio. I'm a senior health ...

On Thursday, Atai announced that it and its clinical partner Beckley Psytech had received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for their investigational ...

Atai Life Sciences is focused on developing new drug treatments for mental health disorders that do not respond well to existing therapies. Its lead programs target conditions like treatment-resistant ...

In case you aren't familiar, Atai is a biotech that's developing a handful of mental health treatments based on psychedelic molecules like MDMA via several subsidiaries and variable-interest entities.